Tyrosine kinase inhibitors (TKIs) lead to similar outcomes across racial and ethnic groups when used to treat acute myeloid ...

Zongertinib demonstrates promising efficacy in HER2-mutated NSCLC, with a 69% PFS rate and 73% duration of response over 6 months. The investigational TKI shows a favorable toxicity profile, with ...

Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they ...

Currently, although there are many options for cancer immunotherapy, they still cannot meet the needs of clinical treatment, especially for advanced solid tumors defined as 'cold tumors'. Genetic ...

Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to ...

New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success ...